Significant Ownership of Avoro Capital Advisors LLC

Signature - Title
/s/ Scott Epstein - Scott Epstein, Chief Operating Officer and Chief Compliance Officer
Location
New York, NY
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Avoro Capital Advisors LLC.

Notify me when Avoro Capital Advisors LLC files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of Avoro Capital Advisors LLC

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
WHWK Aadi Bioscience, Inc. Common stock, par value $0.0001 per share 20% $18,349,040 +$12,832,820 11,914,961 +233% BEHZAD AGHAZADEH 28 Feb 2025
CNTA Centessa Pharmaceuticals plc Ordinary shares, nominal value 0.002 GBP per share 10% $364,034,431 +$93,724,350 14,555,555 +35% Avoro Capital Advisors LLC 31 Dec 2025
TRML Tourmaline Bio, Inc. Common Stock, par value $0.0001 per share 10% $41,374,435 2,555,555 Avoro Capital Advisors LLC 30 Jun 2025
QURE uniQure N.V. Ordinary Shares, par value EUR0.05 per share 9.9% $143,848,500 +$59,059,750 6,150,000 +70% Avoro Capital Advisors LLC 31 Dec 2025
GPCR Structure Therapeutics Inc. Ordinary Shares, par value $0.0001 per share 9.4% $454,066,620 16,216,665 Avoro Capital Advisors LLC 30 Sep 2025
VERA Vera Therapeutics, Inc. Class A Common Stock, $0.001 par value per share 8.9% $134,640,000 5,610,000 Avoro Capital Advisors LLC 31 Dec 2024
ARWR ARROWHEAD PHARMACEUTICALS, INC. Common Stock, par value $0.001 per share 8.3% $193,377,834 -$8,581,554 11,517,441 -4.2% Avoro Capital Advisors LLC 30 Jun 2025
CELC Celcuity Inc. Common Stock, par value $0.001 per share 6.7% $324,208,877 3,111,111 Avoro Capital Advisors LLC 31 Dec 2025
RNA Avidity Biosciences, Inc. Common Stock, par value $0.0001 per share 5.5% $614,244,077 8,515,792 Avoro Capital Advisors LLC 31 Dec 2025
SLNO SOLENO THERAPEUTICS INC Common Stock, par value $0.001 per share 5.4% $120,379,000 +$35,283,500 2,900,000 +41% Avoro Capital Advisors LLC 31 Dec 2025
Definium Therapeutics, Inc. Common Shares, no par value per share 5.1% 5,000,000 Avoro Capital Advisors LLC 31 Dec 2025
FOLD AMICUS THERAPEUTICS, INC. Common Stock, par value $0.01 per share 4.9% $118,397,000 -$43,143,000 15,025,000 -27% Avoro Capital Advisors LLC 30 Sep 2025
BCRX BIOCRYST PHARMACEUTICALS INC Common Stock, $0.01 par value 4.2% $71,514,000 8,700,000 Avoro Capital Advisors LLC 31 Mar 2025
MLTX MoonLake Immunotherapeutics Class A Ordinary Shares, par value $0.0001 per share 3.2% $14,340,000 -$15,415,500 2,000,000 -52% Avoro Capital Advisors LLC 30 Sep 2025
BPMC Blueprint Medicines Corp Common Stock, par value $0.001 per share 0.6% $48,206,250 -$446,711,250 375,000 -90% Avoro Capital Advisors LLC 30 Jun 2025
GLUE Monte Rosa Therapeutics, Inc. Common Stock, par value $0.0001 per share 0% $0 -$27,602,250 0 -100% Avoro Capital Advisors LLC 30 Sep 2025

Schedules 13D/G Reported by Avoro Capital Advisors LLC:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.